Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh

Department of Cardiovascular Medicine

Professor, University and Royal Infirmary

Edinburgh, United Kingdom

Related Videos

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor? Video

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor? Video

How should the fact that CV risk is not binary, but progressive, influence the decision to use a PCSK9 inhibitor?

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated? Video

Although 70 mg/dL is the target threshold identified by both ESC and AHA, should the interventionalist, in a patient who has just undergone a PCI and has an LDL-C of 69 mg/dL, be considered adequately CV risk-mitigated?